## Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in this application.


- (currently amended) A chimeric, humanized or human antibody that eompetitively inhibits binding of an amphiregulin polypeptide to an epidermal growth factor receptor antiamphiregulin antibody, wherein the amphiregulin polypeptide consists essentially of SEQ ID NO: 1, and wherein the anti-amphiregulin antibody comprises a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 12 and a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 5 and 14. a heavy chain variable region defined by SEQ ID NO: 3; a heavy chain variable region defined by SEQ ID NO: 4 and a light chain variable region defined by SEQ ID NO: 5; or a heavy chain variable region defined by SEQ ID NO: 14.
- 2. (cancelled)
- 3. (currently amended) The antibody of claim 1, wherein the anti-amphiregulin antibody is selected from the group consisting of: an antibody comprising SEQ ID NO: 2 and SEQ ID NO: 3; an antibody comprising SEQ ID NO: 4 and SEQ ID NO: 5; and an antibody comprising SEQ ID NO: 12 and SEQ ID NO: 14. comprises a heavy chain variable region defined by SEQ ID NO: 2 and a light chain variable region defined by SEQ ID NO: 3.
- 4. (currently amended) The antibody of claim 1, wherein the antibody comprises SEQ ID NO: 12 and a light chain variable region defined by SEQ ID NO: 12 and a light chain variable region defined by SEQ ID NO: 14.
- 5. (original) The antibody of claim 1, wherein the antibody is an antibody fragment.
- 6. (original) The antibody of claim 5, wherein the antibody fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.

- 7. (original) The antibody of claim 1, wherein the antibody is conjugated to an effector moiety.
- 8. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a cancer cell.
- 9. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a skin cell.
- 10. (cancelled)
- 11. (cancelled)
- 12. (cancelled)
- 13. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1.
- 14. (original) The pharmaceutical composition of claim 13, wherein the antibody is conjugated to an effector moiety.
- 15. (original) The pharmaceutical composition of claim 13, wherein the antibody comprises SEQ ID NO: 12 and SEQ ID NO: 14.
- 16. (cancelled)
- 17. (cancelled)
- 18. (currently amended) The antibody of claim 1, wherein the antibody comprises a heavy chain variable region defined by SEQ ID NO: 4 and a light chain variable region defined by SEQ ID NO: 5. A chimeric, humanized or human antibody that specifically binds to an amphiregulin polypeptide, wherein the amphiregulin polypeptide consists essentially of SEQ ID NO: 1, and wherein the antibody binds to the same amphiregulin epitope as that bound by an antibody selected from the group consisting of: an antibody comprising a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 3; an antibody comprising a heavy chain variable region of SEQ ID NO: 4 and a light chain

variable region of SEQ ID NO: 5; and an antibody comprising a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.

19. (cancelled)

20. (cancelled)
21. (currently amended) The antibody of claim $\frac{1}{4}$ , wherein the antibody inhibits proliferation of tumor cells.
22. (currently amended) The antibody of claim <u>1</u> <del>18</del> , wherein the antibody inhibits <i>in vivo</i> proliferation of tumor cells that express amphiregulin.
23. (currently amended) The antibody of claim <u>1</u> <del>18</del> , wherein the antibody neutralizes at least one biological activity of amphiregulin.
24. (currently amended) The antibody of claim <u>1</u> <del>18</del> , wherein the antibody is conjugated to an effector moiety.
25. (currently amended) The antibody of claim <u>1</u> <del>18</del> , wherein the antibody competes for binding to the ligand binding site of a ligand of amphiregulin.
26. (cancelled)
27. (cancelled)
28. (currently amended) A hybridoma producing the antibody of claim $\underline{1}$ 18.
29. (cancelled)
30. (cancelled)
31. (cancelled)
32. (currently amended) A An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 12 and 14.



- 47. (currently amended) The A chimeric, humanized or human antibody of claim 46, wherein the antibody comprises comprising a heavy chain variable region defined by of SEQ ID NO: 2 and a light chain variable region defined by of SEQ ID NO: 3.
- 48. (currently amended) The A chimeric, humanized or human antibody of claim 46, wherein the antibody comprises comprising a heavy chain variable region defined by of SEQ ID NO: 4 and a light chain variable region defined by of SEQ ID NO: 5.
- 49. (currently amended) The A chimeric, humanized or human antibody of claim 46, wherein the antibody comprises comprising a heavy chain variable region defined by of SEQ ID NO: 12 and a light chain variable region defined by of SEQ ID NO: 14.

- 50. (new) The antibody of claim 49, wherein the antibody is an antigen binding fragment that is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.
- 51. (new) The antibody of claim 49, wherein the antibody is conjugated to an effector moiety.
- 52. (new) A pharmaceutical composition comprising the antibody of claim 49 and a pharmaceutically acceptable excipient.